Department of Cardiology, Xijing Hospital The Fourth Military Medical University Xi'an Shaanxi China.
Cadet Brigade, School of Basic Medicine The Fourth Military Medical University Xi'an Shaanxi China.
J Am Heart Assoc. 2023 Apr 18;12(8):e029034. doi: 10.1161/JAHA.123.029034. Epub 2023 Apr 7.
Background Data regarding the impact of successful chronic total occlusion treated with percutaneous coronary intervention (CTO-PCI) on symptoms and quality of life (QOL) in elderly patients (≥75 years) are unknown. This prospective study aimed to assess whether successful CTO-PCI could improve the symptoms and QOL in elderly patients (≥75 years). Methods and Results Consecutive patients who underwent elective CTO-PCI were prospectively enrolled and subdivided into 3 groups based on age: age<65 years, 65 years≤age<75 years, and age≥75 years. The primary outcomes included symptoms, as assessed with the New York Heart Association functional class and Seattle Angina Questionnaire, and QOL, as assessed with the 12-Item Short-Form Health Survey questionnaire, at baseline, 1 month, and 1 year after successful CTO-PCI. Of 1076 patients with CTO, 101 were age≥75 years (9.39%). Hemoglobin, estimated glomerular filtration rate, and left ventricular ejection fraction levels all decreased with increasing age, and NT-proBNP (N-terminal pro-B-type natriuretic peptide) increased. The proportion of dyspnea and coronary lesions, including multivessel disease, multi-CTO lesion, and calcification were higher in elderly patients. Procedural success rate, intraprocedural complications, and in-hospital major adverse cardiac events were not statistically different in the 3 groups. Importantly, symptoms, including dyspnea and angina, were markedly improved regardless of age at 1-month and 1-year follow-up (<0.05). Likewise, successful CTO-PCI significantly improved QOL at 1-month and 1-year follow-up (<0.01). Additionally, the incidence of major adverse cardiac events and all-cause mortality at 1-month and 1-year follow-up was not statistically different in the 3 groups. Conclusions Successful PCI was beneficial and feasible to improve symptoms and QOL in patients ≥75 years of age with CTO.
背景 关于经皮冠状动脉介入治疗(CTO-PCI)成功治疗慢性完全闭塞病变(CTO)对 75 岁以上老年患者症状和生活质量(QOL)影响的数据尚不清楚。本前瞻性研究旨在评估 CTO-PCI 成功是否可以改善 75 岁以上老年患者的症状和 QOL。
方法和结果 连续入选接受选择性 CTO-PCI 的患者,并根据年龄分为 3 组:年龄<65 岁、65 岁≤年龄<75 岁和年龄≥75 岁。主要结局包括纽约心脏协会功能分级和西雅图心绞痛问卷评估的症状以及 12 项简明健康调查量表问卷评估的 QOL,在 CTO-PCI 成功后基线、1 个月和 1 年时进行评估。在 1076 例 CTO 患者中,有 101 例(9.39%)年龄≥75 岁。血红蛋白、估算肾小球滤过率和左心室射血分数随年龄增加而降低,NT-proBNP(N 末端 B 型利钠肽原)升高。呼吸困难的比例和包括多支血管病变、多 CTO 病变和钙化在内的冠状动脉病变在老年患者中更高。3 组间的手术成功率、术中并发症和住院期间主要不良心脏事件无统计学差异。重要的是,无论年龄大小,1 个月和 1 年随访时,症状(包括呼吸困难和心绞痛)均明显改善(<0.05)。同样,1 个月和 1 年随访时 CTO-PCI 成功显著改善了 QOL(<0.01)。此外,3 组间 1 个月和 1 年随访时主要不良心脏事件和全因死亡率无统计学差异。
结论 CTO-PCI 成功对 75 岁以上老年 CTO 患者的症状和 QOL 有益且可行。